BofA moved to No Rating on Avidity Biosciences (RNA) after the company announced that it has entered into an agreement to be acquired by Novartis (NVS) for about $12B, or $72 per share. Given the deal, the stock is no longer trading on fundamentals, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: